Skip to main content
. 2019 Sep 4;10:2088. doi: 10.3389/fimmu.2019.02088

Figure 5.

Figure 5

Inhibition of IL-1R decreases DVT in 4T1 tumor-bearing mice. (A) Systemic levels of G-CSF in 4T1 tumor-bearing mice (black bars, n = 5) and 4T1 tumor-bearing mice treated with anakinra (gray bars, n = 6) were assessed by a specific ELISA kit as described in section Materials and Methods. (B) The neutrophil count in mice with 4T1 (black bars, n = 11) or anakinra-treated 4T1 (gray bars, n = 7) tumors was evaluated as described in section Materials and Methods. Two systemic markers of NETs, MPO (C) and cfDNA (D), were analyzed in 4T1 tumor-bearing mice (black bars, n = 6) and 4T1 tumor-bearing mice treated with the IL-1R antagonist (gray bars, n = 6) as described in section Materials and Methods. For systemic analysis, the blood was collected 21 days after the tumor cell inoculation. (E) Venous thrombosis was evaluated with stasis of the inferior vena cava for 6 h in 4T1 tumor-bearing mice (•, n = 15) and 4T1 tumor-bearing mice treated with anakinra (■, n = 14). (F) Alternatively, 4T1 tumor-bearing mice (•, n = 15) were treated with MCC950 (20 mg/kg/day, s.c.) (■, n = 4) for 8 days, between day 14 and day 21 after the tumor cell inoculation. Each dot represents one individual mouse. Values represent the mean ± SD. *P < 0.05 and **P = 0.01; n.s., non-significant, unpaired two-tailed Student's t-test.